Inclusion criteria:
male or female aged 55-80 years at the time of signing the informed consent form.
Patients with Primary active CNV subfoveal lesion secondary to AMD (with definite diagnosis of AMD according to physician’s decision based on the results of ocular examination, or OCT)
the ETDRS-best-corrected visual acuity index with the score of 20/40 to 20/320 (or BCVA letter score of 73 to 25 in the study eye)
Willing, committed, and able to return for clinic visits and complete all study-related procedures
Patients with the ability to read, understand and willing to sign the informed consent form for participation in the study
Exclusion criteria:
Any prior ocular (in the study eye) or systemic anti-VEGF therapy, during the past 3 months, Photodynamic Therapy (PDT) or surgery for neovascular AMD.
The need for receiving ocular anti-VEGF simultaneously in both eyes in the loading phase for the treatment of neovascular AMD
Scar, fibrosis, or extensive subretinal hemorrhage of more than 50% of the total lesion area in the study eye, according to the physician's opinion based on clinical presentation or according to fundus photography.
The presence of scar, fibrosis, or atrophy in the central part of the fovea in the study eye
The presence of retinal pigment epithelial tears or rips involving the macular part of the study eye at the time of entering the study
The history of any vitreous hemorrhage within 4 weeks prior to the first visit of the study in the study eye
Presence of other causes of CNV in the study eye
Clinical or paraclinical diagnosis of PCV by physician’s diagnosis
The history or clinical evidence of diabetic retinopathy, diabetic macular edema, or any other vascular disease affecting the retina, other than AMD in either eyes
Prior vitrectomy in the study eye
History of retinal detachment or treatment or surgery for retinal detachment in the study eye
Any history of a macular hole of stage 2 or above in the study eye
Any intraocular or periocular surgery within three months of the screening visit on the study eye except lid surgery, which may not have taken place within one month of screening visit
Prior trabeculectomy or any other filtration surgery in the study eye
Uncontrolled glaucoma (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma medication) in the study eye
Active intraocular inflammation in either eye
Active ocular or periocular infection in either eye or any ocular or periocular infection within the last two weeks prior to screening visit in either eye
Any history of uveitis in either eye
Presence or history of scleromalacia in either eye
Aphakia or pseudophakia with the absence of posterior capsule (unless it occurred as a result of a yttrium aluminum garnet [YAG] posterior capsulotomy) in the study eye
Previous therapeutic radiation in the region of the study eye
History of corneal transplant or corneal dystrophy in the study eye
Any significant media opacities, including cataract, in the study eye that might interfere with visual acuity, assessment of drug safety, or fundus photography
Patients with amblyopia.
Patients with blindness in the fellow eye
Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could require either medical or surgical intervention during the study period
Any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the patient beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety
History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk for treatment complications
Participation as a patient in any clinical study within the 12 weeks prior to the screening visit
The use of long-acting steroids, either systemically or intraocularly, in the six months prior to screening visit
Any history of allergy to povidone iodine
Females who are pregnant, breastfeeding, planning to become pregnant during the study period, unwilling to practice adequate contraception throughout the study and for at least 60 days following the last dose of study medication
History of stroke, myocardial infarction or uncontrolled hypertension (blood pressure >160/100 despite receiving medical treatment) for less than three months from the date of the Screening visit
Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders